Company: SCLXW
Filing Date: 2025-12-16
Form Type: S-1
Source: 0001193125-25-319720
Chunk: 237

Company: Scilex Holding Co
Filing Date: 2025-12-16
Form: S-1
Chunk 237
---
 outstanding equity interests of Legacy Semnur and Denali. Semnur’s common stock and warrants were listed on the OTC Markets Group, Inc. on September 23, 2025 under the new ticker symbols “SMNR” and “SMNRW”, respectively. Digital Assets On September 23, 2025, as part of our cryptocurrency acquisition and treasury strategy, we entered into a securities purchase agreement with Biconomy PTE Ltd (“Biconomy”), pursuant to which we sold to Biconomy an aggregate of 12,500,000 shares of Semnur Common Stock held by us for proceeds of $200.0 million in Bitcoin. Future Liquidity Needs We have based our anticipated operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect. The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to:

| • |     | the costs and expenses associated with our ongoing commercialization efforts for ZTlido, GLOPERBA and ELYXYB; |

| • |     | the degree of success we experience in commercializing ZTlido, GLOPERBA and ELYXYB; |

| • |     | the revenue generated by sales of ZTlido, GLOPERBA, ELYXYB and other products that may be approved, if any; |

| • |     | the scope, progress, results and costs of conducting studies and clinical trials for our product candidates, SEMDEXA, SP-103 and SP-104; |

| • |     | the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates; |

| • |     | the costs of manufacturing ZTlido, GLOPERBA, ELYXYB and our product candidates; |

| • |     | the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current or future collaboration or license agreements; |

156

| • |     | our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; |

| • |     | the extent to which ZTlido, GLOPERBA, ELYXYB or any of our product candidates, if approved for commercialization